CBD’s inclusion in U.S. system that tracks health risks is double-edged sword

The U.S. Food and Drug Administration (FDA) has formally added hemp-derived cannabinoids such as CBD to the list of categories it monitors, marking the first time the agency will collect targeted data on consumer-reported health incidents tied to products containing such compounds.

FDA’s long-standing system for collecting reports on health problems linked to medical products, MedWatch, takes voluntary submissions from patients, healthcare providers and companies, and helps the agency spot safety issues.

The new category, defined as “Cannabinoid Hemp Products (such as products containing CBD),” is now included on standard forms used by consumers to report to the program.

Cutting both ways

The MedWatch listing presents both opportunity and risk for the CBD sector. A distinct reporting category for CBD promises more precise data. Until now, incidents involving CBD were scattered across broader drug or supplement categories, limiting the FDA’s ability to draw clear conclusions. The new reporting category could help FDA identify genuine safety signals, distinguish between lower- and higher-risk products, and build the evidence needed for sensible regulation.

Stronger data could also lead to dosage caps, product-type restrictions or standardized labeling, outcomes that might also increase clarity in an unsettled marketplace.

Serious risks

But there are risks. MedWatch relies on people reporting problems voluntarily, and the reports often don’t include key details like dosage, other substances taken, or existing health issues. Such reports can overstate connections between a product and a health effect. A handful of dramatic cases can generate headlines out of proportion to actual risk, amplifying the stigma against CBD and hemp.

This is particularly problematic because regulators and media often fail to distinguish between non-intoxicating CBD and synthetic or semi-synthetic cannabinoids such as delta-8 THC – which are made from CBD. The reality is that CBD’s reputation is already being tarnished by association with the intoxicating hemp phenomenon, even though risks differ substantially between the compounds.

Market effect

Market implications are also significant. A wave of negative reports, however unverified, could discourage retailers from carrying CBD products, slow investor interest, and deepen the contraction already underway among producers of over-the-counter CBD health products such as oils and tinctures.

Companies that have spent money on testing and compliance could be overshadowed by broad safety concerns. Meanwhile, if regulators keep delaying decisions while reviewing more “adverse event” reports, the market’s uncertainty could drag on instead of being resolved.

Health considerations

The safety debate around CBD is not new. FDA has consistently argued that more data is needed to establish a clear safety profile, particularly for long-term use and in vulnerable populations. Concerns center on potential liver toxicity, drug interactions, reproductive health effects and impacts on hormone function. Some studies also suggest sedation and appetite changes at higher doses.

European regulators have flagged similar concerns. The European Food Safety Authority (EFSA) has yet to confirm the safety of CBD as a novel food, pointing to gaps in research on how it affects different parts of the body. The UK’s Food Standards Agency has advised vulnerable groups not to consume CBD.

Satisfied consumers

Research is still emerging. Clinical trials confirm CBD’s therapeutic use in rare seizure disorders, but also document liver enzyme elevations and other side effects. A review published earlier this year found that people who take CBD are more likely to feel sleepy, eat less, and have higher liver enzyme levels than those who took a placebo. Another line of research indicates that CBD can influence the metabolism of other drugs, raising the risk of interactions in patients taking multiple medications.

At the same time, consumer experience worldwide suggests that low- and mid-dose CBD products are widely used without major incident. Millions of consumers have incorporated CBD oils, capsules, or gummies into their wellness routines, often reporting benefits such as improved sleep or reduced anxiety.

State-level dynamics

FDA’s action comes as states continue to grapple with their own approaches to hemp cannabinoids. New York has introduced strict limits on THC content in CBD products and requires testing to verify safety. The crackdown has already had “immediate and catastrophic effect” on the state’s CBD market.

In other state-level skirmishes, California has passed laws allowing non-intoxicating CBD, but under strictly defined rules. Colorado, an early adopter of hemp regulation, has set detailed labeling and testing requirements. (Both states have essentially banned synthetic intoxicants such as delta-8 THC, which, again, is made from hemp-derived CBD).

Regulatory vacuum

The state-level interventions reflect both consumer safety concerns and the regulatory vacuum left by the FDA’s slow pace in setting regulations for hemp. With CBD now explicitly included in MedWatch, federal authorities will be better positioned to shape a uniform policy. In the meantime, the patchwork of state rules continues to complicate national distribution, creating both compliance challenges and opportunities for companies that can meet the most stringent standards.

The FDA’s move to track CBD through MedWatch could increase worries and confusion, but it might also help build the evidence needed to finally shape U.S. rules for hemp-derived cannabinoids.

Tracking CBD through MedWatch can make products safer by highlighting real risks and giving regulators better information. The hard part is weighing personal stories against clinical data and finding the right balance between caution and access. Responsible stakeholders know that when it comes to consumer health, it’s better to err on the side of safety.